Biologics Market Size & Forecast Report, 2014 - 2025

Synopsis:

The scope of the global Biologics Market was appreciated at US$ 276.6 billion during 2015. It is expected to reach US$ 399.5 billion by the completion of 2025. It will progress at the CAGR of 3.9%. Outline of targeted treatments together with increasing acceptance of patient centric custom-made medication is expected to power the demand. Always growing understanding of the cell structure and pressure, along with the features involved in the manufacturing of protein and appearance of heterologous gene, have permitted the usage of dissimilar alive factories.

These alive factories are the eukaryotic and prokaryotic cells. Improvement of the functionality of the medicine over attaining effective folding of protein and post translational alterations is helpful for estimated degree of development.

The biologics or biologic medicine is a manufactured using alive creatures or else comprise constituents of a live animals. They can be resulting from the bacteria, animal or humanoid by way of utilizing methods of biotechnology. Biologics comprises products for example recombinant therapeutic proteins, gene treatment, allergenic, vaccines, tissues, somatic cells and blood & blood constituents. Maximum biologics are multifaceted combinations that cannot be categorized or identified without any difficulty. These are sensitive to heat and prone to bacteriological adulteration.

Drivers:

The driving factors of the biologics market consist of large trade-marked tag medicines are losing extensions of their patent, increasing occurrence of long-lasting sicknesses and their diagnoses all over the world, augmented obtainability of cutting-edge diagnostics, increasing initiatives by government in healthcare and rising technical progressions in research and development through the world by giant medicine manufacturers to bear competition and capitalize in incremental invention. Additional reasons growing the demand for biologic medicines consist of increasing governing convergence and superior admittance to healthcare for altogether nation-states. Increasing acceptance of the state-of-the-art remedies for the treatment of numerous complaints will too enlarge the development of the market for the duration of the forecast

Restraints:

The restricting factors for the market consist of difficulty in production, because the medicines are extremely multifaceted in nature. They need to be treated under strongly measured situations, preserved during the course of the manufacturing procedure. This category of atmosphere and the processes of quality control are not effortlessly obtainable in not as much of urbanized nation-states. Ecological adulteration requires to be removed from the procedure of production. Additionally, biologics are tremendously prone to the circumstances of heat and light, and require exceptionally good cooling procedures. This is not existing consistently all over the world. Similarly, strict governing necessities for the market endorsement of biologics may possibly will restrict the market for biologics for the duration of the specified time structure.

Classification:

The global biologics industry can be classified by Manufacturing, Illness Type, Product, Source, and Region. By Manufacturing, it can be classified as In-house, Subcontracted. By Illness Type, it can be classified as Hematological Disorders, Immunological Disorders, Oncology, Cardiovascular Disorders, Infectious Diseases, and others. By Product, it can be classified as Monoclonal Antibodies, Antisense, RNAi, & Molecular Therapy, Vaccines, Recombinant Proteins. By Source, it can be classified as Mammalian, Microbial and others.

Regional Lookout:

By Region the global biologics market can be classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Due to the existence of important recognized companies in this region, North America ruled the market, by way of income generation. Furthermore, greater demand for the products for the treatment of illnesses is qualifying for bigger share of income. Moreover to this, the pharmacological companies of the U.S.A. constitute 80% share of the world’s R&D in the sector of health care biotechnology. The said point is helpful for the projected income of North America.

The Asian contract companies are providing substantial funds so as to grasp the share in market. Companies like Wuxi Biologics and Samsung Biologics are expected to motivate the development in the sector of Asia.

Companies:

Some of the important companies for biologics market are Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi, Amgen, Cell Trion, Samsung Biologics, Novo Nordisk A/S, Pfizer Inc., AbbVie Inc., Add gene, F Hoffman La Roche and Eli Lilly & Company. Additional notable companies are: Lund beck, Genzyme, AstraZeneca, Smiths Medical, Retractable Technologies, Inc., Novartis AG, GSK Biologicals, Bayer AG, Terumo Corporation, Becton, Dickinson & Company, and Unilife Corporation.

Market Segment:

Biologics Source Outlook (Revenue, USD Billion, 2014 - 2025)
    • Microbial
    • Mammalian
    • Others

Biologics Product Outlook (Revenue, USD Billion, 2014 - 2025)
    • Monoclonal Antibodies
        • By application
            • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
            • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
            • Protein Purification
            • Others
        • By type
            • Murine
            • Chimeric
            • Humanized
            • Human
            • Others
        • Vaccines
        • Recombinant Proteins
        • Antisense, RNAi, & Molecular Therapy
        • Others

Biologics Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
    • In-house
    • Outsourced

Biologics Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
    • Oncology
        • By Product
            • MABs
            • Vaccines
            • Recombinant Proteins
            • Antisense, RNAi, & Molecular Therapy
            • Others (Certain products under trials related to blood products etc)
    • Infectious Diseases
        • By Product
            • Vaccines
            • MABs
            • Antisense, RNAi, & Molecular Therapy
            • Recombinant Proteins
            • Others
    • Immunological Disorders
    • Cardiovascular Disorders
    • Hematological Disorders
    • Others

Biologics Regional Outlook (Revenue, USD Billion, 2014 - 2025)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • UK
    • Asia Pacific
        • Japan
        • China
    • Latin America
        • Brazil
    • Middle East and Africa (MEA)
        • South Africa